Physician profile
Jonathan Eichorn
NPI 1588089783
$1,104.98
in general payments reported to CMS, 2019-2025
19 companies · $229 in 2025
The $229 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.80 · 2020: $114 · 2021: $57.87 · 2022: $116 · 2023: $327 · 2024: $219 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $774.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $774.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $196.20 | 2021-2025 | |
| Pfizer INC. | $163.38 | 2019-2025 | |
| Allergan, INC. | $100.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $88.34 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $81.69 | 2020-2023 | Xarelto |
| Abiomed | $76.87 | 2024-2025 | Impella |
| Inari Medical, INC. | $71.65 | 2021-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Recor Medical INC | $58.42 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Stryker Corporation | $46.39 | 2025 | Flowtriever |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.70 | 2023-2024 | Jardiance |
| Boston Scientific Corporation | $27.20 | 2024 | Watchman Flx |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.07 | 2025 | Xifaxan |
| Shionogi INC | $22.06 | 2022 | |
| Atricure, INC. | $21.99 | 2024 | |
| Gilead Sciences, INC. | $20.06 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Strongbridge US INC. | $18.74 | 2019 | |
| Bioxcel Therapeutics, INC. | $17.57 | 2023 | Igalmi |
| Astrazeneca Pharmaceuticals LP | $13.34 | 2024 | Lokelma |
| Astellas Pharma US INC | $12.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Eichorn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.